SCM
ALPN

Soleus Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Soleus Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-88,073
Closed -$1.01M – 106
2023
Q3 		$1.01M Hold
88,073
– – 0.09% 81
2023
Q2 		$905K Buy
+88,073
New +$794K 0.1% 86
2021
Q2 		– Sell
-313,064
Closed -$3.32M – 81
2021
Q1 		$3.32M Buy
313,064
+272,000
+662% +$3.39M 0.6% 36
2020
Q4 		$517K Buy
+41,064
New +$403K 0.07% 62

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Soleus Capital Management's ALPN Position: Q4 2023 in Review

Soleus Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2023, closing a stake of 88,073 shares — an estimated $1.01M sold.

Soleus Capital Management first reported a position in ALPN in Q4 2020 and held it in 4 quarters. The position peaked at $3.32M in Q1 2021. 133 funds tracked by Wall St. Rank hold ALPN as of Q4 2023.

  • Soleus Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 88,073 Alpine Immune Sciences Inc shares in Q4 2023, an estimated $1.01M.
  • Soleus Capital Management first reported a position in Alpine Immune Sciences Inc in Q4 2020 and held it in 4 quarters.
  • Soleus Capital Management's Alpine Immune Sciences Inc position peaked at $3.32M in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.